Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Next Previous
Trial Profile

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tominersen (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals; Roche

    • Most Recent Events

    • 27 Apr 2023 Results of pooled post hoc analysis assessing utility of plasma neurofilament light chain (pNfL) as a biomarker of neurodegenerative diseases using a fixed threshold for screening in clinical practice from (NCT03664804, NCT03664804, NCT03100149, NCT01194570) presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 22 Sep 2021 Results from NCT03342053 and other studies exploring associations between remote monitoring of cognitive and motor functions and digitally administered, self-assessed EuroQol 5-dimension 5-level, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
    • 22 Sep 2021 Results the association of smartphone-based active tests in the Roche Huntington's disease (HD) Digital Monitoring Platform (dMP) with brain imaging, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top